GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Esr1 | increases activity | ISO | ESR1 (Homo sapiens) | 6480464 | CTD | triphenyl phosphate metabolite results in increased activity of ESR1 protein; triphenyl phosphate results in increased activity of ESR1 protein | PMID:24051214 PMID:24844797 PMID:26778350 PMID:28728110 | Esr1 | multiple interactions | ISO | Esr1 (Mus musculus) | 6480464 | CTD | [tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of ESR1 mRNA; [tris(1,3-dichloro-2-propyl)phosphate co-treated with Tritolyl Phosphates co-treated with triphenyl phosphate] results in increased expression of ESR1 mRNA; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of and results in decreased secretion of INS1 protein]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of and results in decreased secretion of LEP protein]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of CARTPT mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of CD36 mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of CYP4A10 mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of GHSR mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of NPY mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in decreased expression of NR0B2 mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of CACNA1G mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of CACNA1H mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of CACNA1I mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of GHSR mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of INSR mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of KCNQ2 mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of KCNQ3 mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of KCNQ5 mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of KISS1 mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of LEPR mRNA]; ESR1 gene mutant form inhibits the reaction [[tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] results in increased expression of TRPC5 mRNA]; ESR1 gene mutant form results in decreased susceptibility to [tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with Tritolyl Phosphates] | PMID:29112739 PMID:32360330 | Esr1 | multiple interactions | ISO | ESR1 (Homo sapiens) | 6480464 | CTD | triphenyl phosphate binds to and results in increased activity of ESR1 protein | PMID:23398518 PMID:33049310 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |